FluxMPS™ Dulbecco’s Modified Eagle Medium/ Ham's F-12 Nutrient Mixture (DMEM/F-12) (3:1) with 15mM HEPES w/o L-Glutamine: 1X Liquid

FluxMPS™ Dulbecco’s Modified Eagle Medium/ Ham's F-12 Nutrient Mixture (DMEM/F-12) (3:1) with 15mM HEPES w/o L-Glutamine: 1X Liquid

Microfluidics Suitable, quadruple-stage ultra-filtered (0.1 µm ×2 + 0.04 µm ×2) 1X liquid cell culture medium engineered for microfluidic channels, organ-on-a-chip (OoC), and microphysiological systems (MPS). Manufactured under ISO 13485:2016 in an ISO Class 5 fill environment using Ultrapure Type 1 water (18.2 MΩ·cm). A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration.

• Quadruple-stage 0.04 µm final filtration — 0.1 µm mycoplasma-retentive filtration stages (not tested per lot), sub-micron particulate reduction
• Endotoxin release specification: < 0.05 EU/mL (USP <85> BET, tested per manufacturing batch)
• Dual-buffered: 36.5 mM sodium bicarbonate plus 15 mM HEPES for added pH stability during bench handling
• Manufactured under an ISO 13485:2016 quality management system in an ISO Class 5 fill environment using Ultrapure Type 1 water (18.2 MΩ·cm)
• High-glucose formulation (3.8255 g/L) with sodium pyruvate (27.525 mg/L); L-glutamine excluded — add GlutaMAX™ or L-glutamine at time of use
• 4× BME amino acid & vitamin concentrations for robust long-duration MPS perfusion
• Custom pH, glucose, HEPES, salts & nutrients available — support@diagnocine.com

Engineered where standard media fails

Conventional 0.22 µm filtered media allows mycoplasma (0.2–0.3 µm), sub-visible particulates, and microaggregates to pass freely — clogging microchannels, corrupting biosensors, and interfering with metabolic assays.^[1,2] FluxMPS™ closes that gap.

Quadruple-stage filtration system

This formulation is produced with a validated four-stage sequential filtration process reaching a final pore size of 0.04 µm — capturing sub-micron particulates and mycoplasma-sized organisms that pass through conventional 0.22 µm filtration.

1. 1

   0.1 µm Prefiltration I

   Removes large particulates, cell debris, and protein aggregates. Protects the first 0.04 µm final filter and preserves microchannel chip geometries.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains sub-micron particulates and microaggregates, including organisms in the mycoplasma size range (0.2–0.3 µm).

3. 3

   0.1 µm Prefiltration II

   Second dedicated prefilter, protecting the second 0.04 µm final filter cartridge for redundant bioburden control.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter; aseptic fill in a validated ISO Class 5 (Class 100) laminar-flow workstation.

Optimized for next-generation cell biology platforms

FluxMPS™ DMEM/F-12 (3:1) with 15mM HEPES w/o L-Glutamine is validated for applications where microchannel cleanliness, signal fidelity, and metabolic precision are critical.

Automated Bioreactors & Robotics

For automated perfusion bioreactors and robotic liquid-handling platforms requiring the smallest achievable particulate load, Diagnocine offers an optional 0.01 µm (10 nm) ultra nano-filtered variant of this formulation — the MPS Grade tier of this product line.

• Total Particulate Exclusion — six-stage cascade down to 0.01 µm
• Valve & Sensor Protection — reduces particulate load on microvalves and optical sensors
• Extended Perfusion Stability — supports long-duration unattended runs

Inquiry Required: the 0.01 µm MPS Grade variant is produced to order. Contact support@diagnocine.com to request a quote.

Full technical specification

Every lot of FluxMPS™ DMEM/F-12 (3:1) with 15mM HEPES w/o L-Glutamine is released against multi-parameter QC specifications.

Full composition (mg/L)

Every ingredient below is present in this 1X liquid formulation at the exact concentration listed. Total: 51 components across 4 categories. All values are per-lot verified and reported on the Certificate of Analysis (CoA).

Manufacturing & compliance

Every batch is subjected to multi-parameter release testing before distribution.

How DCP-DMF12H-QT1X compares

Comparison of filtration architecture, mycoplasma control, and QC depth against conventional 0.22 µm filtered media.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ DMEM/F-12 (3:1) with 15mM HEPES w/o L-Glutamine (DCP-DMF12H-QT1X).

Supporting literature

1. Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328:1662–1668. doi:10.1126/science.1188302
2. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760–772. doi:10.1038/nbt.2989
3. Vander Heiden MG, et al. Understanding the Warburg effect. Science. 2009;324:1029–1033. doi:10.1126/science.1160809
4. Sontheimer-Phelps A, et al. Modelling cancer in microfluidic human organs-on-chips. Nat Rev Cancer. 2019;19:65–81. doi:10.1038/s41568-018-0104-6
5. van Duinen V, et al. Microfluidic 3D cell culture. Curr Opin Biotechnol. 2015;35:118–126. doi:10.1016/j.copbio.2015.05.002
6. Jang KJ, et al. Reproducing human drug toxicities using a Liver-Chip. Sci Transl Med. 2019;11:eaax5516. doi:10.1126/scitranslmed.aax5516
7. Kasendra M, et al. Primary human Small Intestine-on-a-Chip. Sci Rep. 2018;8:2871. doi:10.1038/s41598-018-21201-7
8. Skardal A, et al. Multi-tissue organ-on-a-chip platform. Sci Rep. 2017;7:8837. doi:10.1038/s41598-017-08879-x